X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/pharma/vyvgart-firing-all-cylinders-myasthenia-gravis-argenx-lays-launch-plans-next-potential
https://www.globenewswire.com/news-release/2024/04/16/2863272/0/en/argenx-Data-Highlight-Evidence-that-VYVGART-and-VYVGART-Hytrulo-Drive-Transformative-Outcomes-for-Patients-with-Debilitating-Autoimmune-Disease.html
https://www.globenewswire.com/news-release/2024/03/27/2852890/0/en/argenx-Advances-Clinical-Development-of-Efgartigimod-in-Primary-Sjogren-s-Disease.html
https://www.globenewswire.com/news-release/2024/03/26/2852095/0/en/argenx-Announces-Approval-of-VYVGART-efgartigimod-alfa-in-Japan-for-Adults-with-Primary-Immune-Thrombocytopenia.html
https://www.fiercepharma.com/marketing/argenx-goes-again-ramping-unbranded-campaign-ahead-hoped-label-expansion
https://endpts.com/argenx-rolls-out-new-campaign-for-rare-autoimmune-condition-as-it-awaits-fda-ruling/
https://www.globenewswire.com//news-release/2024/02/26/2834787/0/en/argenx-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com//news-release/2024/02/22/2833283/0/en/argenx-to-Report-Full-Year-2023-Financial-Results-and-Fourth-Quarter-Business-Update-on-February-29-2024.html
https://www.globenewswire.com//news-release/2024/02/20/2831497/0/en/argenx-Announces-FDA-Acceptance-of-Supplemental-Biologics-License-Application-with-Priority-Review-for-VYVGART-Hytrulo-in-Chronic-Inflammatory-Demyelinating-Polyneuropathy.html
https://www.globenewswire.com//news-release/2024/01/18/2811228/0/en/argenx-Announces-Approval-of-VYVDURA-efgartigimod-alfa-and-hyaluronidase-qvfc-Injection-for-Subcutaneous-Use-in-Japan-for-Generalized-Myasthenia-Gravis.html
Market Place
Share 
